

Q&A

Drug Development Brand Transition

Beginning June 24, 2021 you will begin to see our brands transition from Covance to the Labcorp brand name in order to highlight the pivotal role Labcorp plays in healthcare and showcase the power of our combined offerings through one powerful, unified brand.

Covance will accomplish the mechanics of the transition to Labcorp branding through company name changes during the summer of 2021. Here are a few quick guidelines on how the Covance to Labcorp Drug Development segment company name changes will and will not impact the Drug Development business.

This name change, unlike mergers or corporate combinations:

- ▶ **IS NOT** going to result in changes to taxpayer IDs, VAT numbers, etc.
- ▶ **IS NOT** going to require immediate amendment of current contracts or study-related materials such as plans, manuals and protocols, but **WILL require** updated names and logos over time.
- ▶ **IS NOT** going to happen on the same day for each company (many company name changes will take place near the end of June and others will occur through the end of September);
- ▶ **IS** going to require updates to templates, i.e., contracts, project plans, associated documents (as related to controlled documents).
- ▶ **IS** going to require updates to registrations and licenses at the country, state and local levels as applicable.
- ▶ **IS** going to require notification of vendors and regulatory bodies as applicable.
- ▶ **IS** going to require thoughtful collaboration across each of the 95 companies affected in about 50 countries.

What is the goal of renaming all of the Covance companies?

The main goal of the renaming activities is to present a unified organization across Labcorp to clients, vendors, patients and our internal teams. By formally changing the company names, we will reduce future confusion and difficulty in complying with tradename registration rules.

What is the scope of this effort?

The changes will be comprehensive ranging from brand identity to company names to templates across all regions and business units. Considering holding companies and operating companies, we expect to rename approximately 95 companies in nearly 50 countries. The rebranding effort in Drug Development will not involve any corporate combinations or reorganization activities. You will see changes to the email domain names of our staff to labcorp.com. Through the transition, the prior email addresses will still reach their recipients, but you will begin to receive emails from labcorp.com addresses near the end of June.

Where can we ask more specific questions about this transition?

Questions can be directed to BrandQuestions@Labcorp.com